The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Saifutdinova K.R.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Sushkov О.I.

State Scientific Centre of Coloproctology, Moscow, Russia

Achkasov S.I.

State Scientific Centre of Coloproctology, Moscow, Russia

Prevention of carcinomatosis in colon cancer

Authors:

Saifutdinova K.R., Sushkov О.I., Achkasov S.I.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2019;(11): 88‑92

DOI: 10.17116/hirurgia201911188

Views: 666

Downloaded: 7

Download PDF (RU)
Contact the author
Table of contents

PREVENTION OF CARCINOMATOSIS IN COLON CANCER
PREVENTION OF CARCINOMATOSIS IN COLON CANCER

To cite this article:

Saifutdinova KR, Sushkov ОI, Achkasov SI. Prevention of carcinomatosis in colon cancer. Pirogov Russian Journal of Surgery. 2019;(11):88‑92. (In Russ.)
https://doi.org/10.17116/hirurgia201911188

 
Подписка 2025-2 (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Close metadata
Recommended articles:
D2 and D3 lymph node dissection for colon cancer. Piro­gov Russian Journal of Surgery. 2024;(7):25-35
Methods of cost-effectiveness evaluation of endo­vascular patent fora­men ovale closure for seco­ndary prevention of cryptogenic stroke. Russian Journal of Preventive Medi­cine. 2024;(6):105-110
Arti­ficial inte­lligence in dermatology: oppo­rtunities and prospects. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(3):246-252
About new possibilities for opti­mizing the postoperative period in tonsillectomy. Russian Bulletin of Otorhinolaryngology. 2024;(4):14-19
Deve­lopment and safety study of a 3D printed middle turbinate splint. Russian Bulletin of Otorhinolaryngology. 2024;(4):30-36
Conversion surgery for gastric cancer with limi­ted peri­toneal carcinomatosis. P.A. Herzen Journal of Onco­logy. 2024;(4):5-10
Combined oral contraception and breast. Aspe­cts of truth. Russian Journal of Human Reproduction. 2024;(4):101-105
Methods for predicting the risks of deve­lopment, course and recu­rrence of rhegmatogenous reti­nal deta­chment. Russian Annals of Ophthalmology. 2024;(4):92-97
Multilevel analysis of morbidity in athletes and redu­ction of health risks. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(3):33-45
Modern scientific and practical approaches to searching for biomarkers of aging. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(3):46-52

Colorectal cancer (CRC) is one of the leading forms of cancer. In 2017, over 72,000 of Russian citizens have been diagnosed with CRC. Cancer stage IV was diagnosed in 18 149 of them. Peritoneal carcinomatosis (PC) is one of the forms of metastatic dissemination throughout the peritoneum. There no any unified and standardized approaches to the treatment or prevention of PC associated with CRC. Therefore, it is advisable to identify PC predictors in patients with colon cancer and prevention measures.

Keywords:

colon cancer
peritoneal dissemination
carcinomatosis
prevention
intra-abdominal chemotherapy
second look operations
free cancer cells

Authors:

Saifutdinova K.R.

Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Sushkov О.I.

State Scientific Centre of Coloproctology, Moscow, Russia

Achkasov S.I.

State Scientific Centre of Coloproctology, Moscow, Russia

List of references:

  1. Kaprin AD, Starinskiy VV, Petrova GV. Zlokachestvennye novoobrazovaniya v Rossii v 2017 (zabolevaemost’ i smertnost’). M.: MNIOI im. PA Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018. (In Russ.) http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf
  2. Kaprin AD, Starinskii VV, Petrova GV. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2017. M.: MNIOI im. PA Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018. (In Russ.) http://www.oncology.ru/service/statistics/condition/2017.pdf
  3. Piso P, Arnold D. Multimodal Treatment Approaches for Peritoneal Carcinosis in Colorectal Cancer. Dtsch Arztebl Int. 2011;108(47):802-808. https://doi.org/10.3238/arztebl.2011.0802
  4. Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Colorectal Dis. 2014;16(5):359-367. https://doi.org/10.1111/codi.12552
  5. Jayne D, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545-1550. https://doi.org/10.1046/j.1365-2168.2002.02274.x
  6. Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, de Hingh IH, Punt CJ. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38(7):617-623. https://doi.org/10.1016/j.ejso.2012.03.008
  7. Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, Germer CT, Pelz JOW. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108(7):1432-1439. https://doi.org/10.1038/bjc.2013.82
  8. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group Phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263-267. https://doi.org/10.1200/JCO.2011.37.1039
  9. Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE, Schlag P. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16(6):83-97. https://www.ncbi.nlm.nih.gov/pubmed/2669141
  10. Faron M, Macovei R, Goere D, Honore C, Benhaim L, Elias D. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann. Surg. Oncol. 2016;23(1):114-119. https://doi.org/10.1245/s10434-015-4627-8
  11. Sugarbaker PH. Revised guidelines for second-look surgery in patients with colon and rectal cancer. Clin Transl Oncol. 2010;12(9):621-628. https://doi.org/10.1007/s12094-010-0567-8
  12. Sugarbaker PH. Improving oncologic outcomes for colorectal cancer at high risk for local–regional recurrence with novel surgical techniques. Expert Rev Gastroenterol Hepatol. 2016;10:205-213. https://doi.org/10.1586/17474124.2016.1110019
  13. Maximiliano G, Huguenin J, Cerebelli C, Benhaim L, Honore C, Elias D, Goéré D. Strategies to prevent peritoneal carcinomatosis arising from colorectal cancer. Future oncology. 2017;13(10):907-918. https://doi.org/10.2217/fon-2016-0389
  14. González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2010;2(2):68-75. https://doi.org/10.4251/wjgo.v2.i2.68
  15. Sugarbaker PH. Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. World J Gastroenterol. 2014;20(28):9286-9291. https://doi.org/10.3748/wjg.v20.i28.9286
  16. Noura S, Ohue M, Shingai T, Kano S, Ohigashi H, Yano M, Ishikawa O, Takenaka A, Murata K, Kameyama M. Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol. 2011;18(2):396-404. https://doi.org/10.1245/s10434-010-1319-2
  17. Sammartino P, Sibio S, Biacchi D, Cardi M, Mingazzini P, Rosati MS, Cornali T, Sollazzo B, Maherfouad Atta J, Di Giorgio A. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Colorectal Dis. 2014;29(9):1081-1089. https://doi.org/10.1007/s00384-014-1929-4
  18. Klaver CEL, Musters GD, Bemelman WA, Punt CJA, Verwaal VJ, Dijkgraaf MGW, Aalbers AGJ, van der Bilt JDW, Boerma D, Bremers AJA, Burger JWA, Buskens CJ, Evers P, van Ginkel RJ, van Grevenstein WMU, Hemmer PHJ, de Hingh IHJT, Lammers LA, van Leeuwen BL, Meijerink WJHJ, Nienhuijs SW, Pon J, Radema SA, van Ramshorst B, Snaebjornsson P, Tuynman JB, te Velde EA, Wiezer MJ, de Wilt JHW, Tanis PJ. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15(1):428. https://doi.org/10.1186/s12885-015-1430-7
  19. Klaver CEL, Stam R, Sloothaak DAM, Crezee J, Bemelman WA, Punt CJA, Tanis PJ. Colorectal cancer at high risk of peritoneal metastases; long term outcomes of a pilot study on adjuvant laparoscopic HIPEC and future perspectives. Oncotarget. 2017;8(31):51200-51209. https://doi.org/10.18632/oncotarget.17158
  20. Tentes AA, Kakolyris S, Pallas N, Korakianitis O, Mavroudis C, Zorbas G, Sarlis P. Preliminary results with the use of hyperthermic intraoperative intraperitoneal chemotherapy or systemic chemotherapy in high-risk colorectal cancer patients. Transl Gastrointest Cancer. 2013;2(1):6-10. https://doi.org/10.3978/j.issn.2224-4778.2012.10.02
  21. Baratti D, Kusamura S, Iusco D, Gimondi S, Pietrantonio F, Milione M, Guaglio M, Bonomi S, Grassi A, Virzì S, Leo E, Deraco M. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. Ann Surg Oncol. 2017;24(1):167-175. https://doi.org/10.1245/s10434-016-5488-5
  22. Arjona-Sánchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Concepción Martín V, García-Fadrique A, Gutiérrez-Calvo A, Morales R, Ortega-Pérez G, Pérez-Viejo E, Prada-Villaverde A, Torres-Melero J, Vicente E, Villarejo-Campos P, Sánchez-Hidalgo JM, Casado-Adam A, García-Martin R, Medina M, Caro T, Villar C, Aranda E, Cano-Osuna MT, Díaz-López C, Torres-Tordera E, Briceño-Delgado FJ, Rufián-Peña S. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer. 2018;18(1):183-191. https://doi.org/10.1186/s12885-018-4096-0
  23. Shelygin YuA, Sushkov OI, Achkasov SI, Ponomarenko AA, Shubin VP, Likhter MS. Repeat cytoreductive surgery and intraperitoneal intraoperative chemotherapy in the treatment of peritoneal carcinomatosis recurrence from colorectal origin. Koloproktologiya. 2017;4(62):67-73. (In Russ.) https://elibrary.ru/item.asp?id=30621933
  24. Wangensteen OH. Cancer of the colon and rectum; with special reference to earlier recognition of alimentary tract malignancy; secondary delayed re-entry of the abdomen in patients exhibiting lymph node involvement; subtotal primary excision of the colon; operation in obstruction. Wis Med J. 1949;48(7):591-597. https://www.ncbi.nlm.nih.gov/pubmed/18134162
  25. Gilbertsen VA, Wangensteen OH. A summary of thirteen years’ experience with the second look program. Surg Gynecol Obstet. 1962;114:438-442. https://www.ncbi.nlm.nih.gov/pubmed/13898554?dopt=Abstract
  26. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following curative surgery for adenocarcinoma of the rectum. Cancer. 1974;34(4):1278-1292. https://doi.org/10.1002/1097-0142(197410)34:4<1278::AID-CNCR2820340440>3.0.CO;2-F
  27. Gunderson LL, Sosin H, Levitt S. Extrapelvic colon-areas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1985;11(4):731-741. https://doi.org/10.1016/0360-3016(85)90305-0
  28. Elias D, Goéré D, Di Pietrantonio D, Boige V, Malka D, Kohneh-Shahri N, Dromain C, Ducreux M. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann. Surg. 2008;247(3):445-450. https://doi.org/10.1097/sla.0b013e31815f0113
  29. Elias D, Honoré C, Dumont F, Ducreux M, Boige V, Malka D, Burtin P, Dromain C, Goéré D. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254(2):289-293. https://doi.org/10.1097/sla.0b013e31822638f6
  30. Serrano del Moral Á, Pérez Viejo E, Manzanedo Romero I, Rodríguez Caravaca G, Pereira Pérez F. Systematic second-look surgery plus HIPEC in patients without evidence of recurrence, at high risk of carcinomatosis after colorectal cancer resection. Cir Esp. 2018;96(2):96-101. https://doi.org/10.1016/j.cireng.2017.11.011
  31. Sushkov OI, Achkasov SI. Peritoneal colorectal carcinomatosis. Approaches to treatment (review). Koloproktologiya. 2016;4(58):69-79. (In Russ.) https://elibrary.ru/item.asp?id=27389687
  32. Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, Raynard B. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after complete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14(6):1818-1824. https://doi.org/10.1245/s10434-007-9348-1
  33. Herzog TJ. The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax? Ann Surg Oncol. 2012;19(13):3998-4000. https://doi.org/10.1245/s10434-012-2521-1
  34. Spiliotis J, Halkia E, de Bree E. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy — current perspectives. Curr Oncol. 2016;23(3):e266-e275. https://doi.org/10.3747/co.23.2831
  35. Goere D, Glehen O, Quenet F, Ducreux M, Guilloit J, Texier M, Benhamou E, Elias D. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP — NTC01226394). Journal of Clinical Oncology. 2018;36(15):3531-3531. https://doi.org/10.1200/JCO.2018.36.15_suppl.3531

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.